What are the best treatments for Hunter syndrome?

Hunter syndrome (Mucopolysaccharidosis II) is primarily treated with enzyme replacement therapy (ERT) to provide the missing iduronate-2-sulfatase enzyme, alongside multidisciplinary supportive care to manage systemic complications. While ERT slows the progression of somatic symptoms, it does not cross the blood-brain barrier, making the management of neurological symptoms a focus of ongoing clinical research.

What are the primary medical treatments for Hunter syndrome?

The standard of care for Hunter syndrome involves weekly intravenous infusions of idursulfase (Elaprase). This enzyme replacement therapy helps the body break down glycosaminoglycans (GAGs), which accumulate in the cells of individuals with Hunter syndrome. For patients with the severe, neuronopathic form of the disease, hematopoietic stem cell transplantation (HSCT) may be considered, though its effectiveness on neurological outcomes remains a subject of clinical debate.

What supportive therapies are used for Hunter syndrome?

Because Hunter syndrome is a multisystemic condition, care must be highly personalized. Non-pharmacological interventions are essential to maintain quality of life:

• Physical and Occupational Therapy: To manage joint contractures and maintain mobility.


• Speech Therapy: To address communication challenges and swallowing difficulties.


• Surgical Interventions: Procedures such as tonsillectomy, adenoidectomy, or carpal tunnel release are frequently required to alleviate airway and nerve compression.


• Cardiac Monitoring: Regular echocardiograms are vital to track valve function.

Which specialists should be on the care team?

Managing Hunter syndrome requires a coordinated, multidisciplinary team. Key specialists include metabolic geneticists, cardiologists, neurologists, otolaryngologists (ENTs), and physical therapists. At DiseaseMaps.org, 66 people with Hunter syndrome have shared their experiences, highlighting the value of connecting with centers of excellence that specialize in lysosomal storage disorders.

Are there emerging treatments for Hunter syndrome?

Medical researchers are currently investigating innovative therapies, including gene therapy and substrate reduction therapy, to better address the neurological manifestations of Hunter syndrome. Clinical trials are the best way to access these experimental options; patients and families are encouraged to consult their metabolic team to see if they meet the criteria for ongoing studies.

Next steps

• Consult a metabolic specialist to review the latest guidelines for Hunter syndrome care.


• Connect with the DiseaseMaps.org community to share experiences with other families.


• Monitor ClinicalTrials.gov for active research programs regarding Hunter syndrome therapies.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice; please consult your clinical team for personalized treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hunter syndrome overview.


• Orphanet: Rare disease database entry for Mucopolysaccharidosis type II.


• National MPS Society: Resources for patients and families affected by MPS II.


• OMIM (Online Mendelian Inheritance in Man): Iduronate-2-sulfatase deficiency data.